跳至主要内容
临床试验/EUCTR2018-001618-13-GB
EUCTR2018-001618-13-GB
进行中(未招募)
1 期

Study to Evaluate Arthroplasty Specimens in the Phase 3 Fasinumab Program for Osteoarthritis of the Knee and Hip

Regeneron Pharmaceuticals, Inc.0 个研究点目标入组 50 人2018年9月25日

概览

阶段
1 期
干预措施
未指定
疾病 / 适应症
Pain due to osteoarthritis of the knee or hip
发起方
Regeneron Pharmaceuticals, Inc.
入组人数
50
状态
进行中(未招募)
最后更新
5年前

概览

简要总结

暂无简介。

注册库
who.int
开始日期
2018年9月25日
结束日期
待定
最后更新
5年前
研究类型
Interventional clinical trial of medicinal product
性别
All

研究者

入排标准

入选标准

  • 1\. Previously randomised to R475\-PN\-1523, R475\-OA\-1611, or R475\-OA\-1688 and received at least 1 dose of study drug
  • 2\. Notified the site that they are planning a knee or hip arthroplasty during the parent study between randomization and 24 weeks after the last dose of SC study drug
  • 3\. Patient’s surgeon/pathologist is willing to coordinate with the site regarding preparation, storage, and shipping of joint tissue samples collected during arthroplasty surgery
  • 4\. Willing and able to comply with clinic visits and study\-related procedures
  • 5\. Provide informed consent signed by study patient or legally acceptable representative
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range 25
  • F.1\.3 Elderly (\>\=65 years) yes

排除标准

  • There are no exclusion criteria for this study.

结局指标

主要结局

未指定

相似试验